KR20170135349A - Composition comprising ginseng seed extracts for prevention and treatment of non-alcoholic fatty liver disease - Google Patents

Abstract

Provided is a pharmaceutical composition for preventing and treating non-alcoholic fatty liver containing a ginseng seed extract. According to the present invention, the composition shows remarkable effects on prevention, treatment, and amelioration of non-alcoholic fatty liver through functions of preventing fat accumulation in liver and improving concentration of fat in blood.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention and treatment of nonalcoholic fatty liver including ginseng seed extract,

The present invention relates to a pharmaceutical composition for preventing and treating non-alcoholic fatty liver and / or hyperlipidemia comprising a ginseng seed extract.

The present invention relates to a health functional food for prevention and improvement of non-alcoholic fatty liver and / or hyperlipidemia comprising ginseng seed extract.

Fatty liver is a state in which triglycerides accumulate in the liver due to fat metabolism in the liver and is defined as fatty liver when the weight percentage of lipid accumulated in the liver is 5% or more. Major causes include excessive drinking and obesity. In the present study, we investigated the effects of dietary habits on the development of non-alcoholic fatty liver disease (NAFLD), which is closely related to recent changes in societal eating habits due to socioeconomic changes. . Non-alcoholic fatty liver is a common cause of chronic liver disease, including non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and liver cancer, which show inflammation of hepatocytes beyond simple fatty liver.

Currently, the main method of nonalcoholic fatty liver therapy is to improve obesity, obesity-induced liver cirrhosis and quality of life by improving lifestyle, but it is difficult to achieve steady weight management and regular exercise, I'm not satisfied. Several pathologic mechanisms such as insulin resistance, oxidative stress, and apoptosis are known to be involved in the pathogenesis of nonalcoholic fatty liver. Many therapeutic agents that work on these mechanisms have been preclinically and clinically tested, but the results are still difficult to interpret It is unfortunate situation. For example, metformin, thiazolidinedione, statin, and antioxidants have been tried. However, no medicines have been established as therapeutic agents until now, Although there are reports of hepatocellular carcinoma, there are few medicines that are recognized as comprehensive treatments including improvement of liver biopsy.

Meanwhile, as the global functional food market is expanded, the demand for functional foods using ginseng, which is one of the main functional foods of Korea, is also increasing. The health functional foods of ginseng ingredients are mainly made from root ginseng. However, research on ginseng seeds and ginseng roots, which are discarded in the processing and processing of ginseng, is still very limited. For example, in the normal ginseng cultivation process, the ginseng flower bud is removed and discarded in order to inhibit the development of the disease and promote root growth, and research and development on such ginseng flower buds has not been systematically carried out yet. However, the Journal of Applied Biological Chemistry 54 (1), 154-157, 2011) reported that the content of ginsenoside Re was 3.46%, 23 times higher than that of ginseng (0.15%).

In addition, no systematic studies have been conducted on ginseng seeds, but ginseng seeds have a ginsenoside Re content of 1.65%, which is about 11 times higher than that of ginseng (0.15%) (Food Sci. Biotechnol. (6), 1379-1382, 2008.), and it was confirmed that ginseng seed oil inhibited? -Glucosidase and? -Amylase.

Until now, the development of drugs for the treatment of nonalcoholic liver diseases has been insufficient, and existing drugs have side effects and the therapeutic effect is weak, so there are few drugs available for prevention, treatment and improvement of nonalcoholic liver disease. Therefore, there is a need for various studies to improve, treat or prevent non-alcoholic liver diseases using natural substances with relatively low side effects.

KR 10-2014-0080982, 2014. 7. 1. KR 10-2013-0143330, December 31, 2013.

The present invention provides a pharmaceutical composition for prevention and treatment of nonalcoholic fatty liver including a ginseng seed extract.

The present invention provides a health functional food for prevention and improvement of a non-alcoholic fatty liver including a ginseng seed extract.

The present invention provides a pharmaceutical composition for preventing and treating hyperlipidemia comprising ginseng seed extract.

The present invention provides a health functional food for prevention and improvement of hyperlipidemia comprising ginseng seed extract.

The inventors of the present invention confirmed that the extract of ginseng seed, which is a ginseng planting and processing wastes product, has a preventive and therapeutic effect on diseases such as non-alcoholic fatty liver disease, arteriosclerosis and hyperlipemia, in order to develop ginseng product with added value and enhanced function, .

The present invention provides a pharmaceutical composition for prevention and treatment of nonalcoholic fatty liver including a ginseng seed extract.

The present invention provides a pharmaceutical composition for prevention and treatment of hyperlipemia comprising ginseng seed extract.

The pharmaceutical composition according to the present invention is effective for prevention and treatment of non-alcoholic fatty liver and / or hyperlipidemia through the action of inhibiting the accumulation of fat in the liver and improving the blood lipid concentration by including ginseng seed extract as an effective ingredient.

The ginseng seeds according to the present invention are ginsengs such as ginseng ( Panax ginseng CA Meyer, Panax quinquefolium , Panax notoginseng ) commonly used as a seed part which can be obtained by removing the flesh part of the ripe ginseng fruit, , jukjeol three (Panax japonicum), a seed of ginseng obtained from three yeopsam (Panax trifolium), Himalayan ginseng (Panax pseudoginseng) or Vietnamese ginseng (Panax vietamensis).

In the present invention, the term "extract" means a substance obtained by extracting components from a natural product, regardless of the extraction method and the kind of the component. For example, it includes those obtained by extracting components dissolved in a solvent from natural products by using water or an organic solvent, and those obtained by extracting only specific components such as oils.

In the present invention, the ginseng seed extract is preferably a ginseng seed oil. "Ginseng seed oil" means an oil obtained from ginseng seeds.

The extract of the ginseng seed according to the present invention can be carried out by extracting the extractant with about 2 to 10 times, preferably 5 to 10 times the weight of the ginseng seed. The extraction solvent may be an organic solvent such as ether. The extraction may be carried out by an extraction method known in the art, for example, a method such as cold-rolling, hot water extraction, ultrasonic extraction, reflux cooling extraction, supercritical extraction, But not limited to,

The ginseng seed extract according to the present invention is preferably a ginseng seed oil extract and may be extracted from ginseng seeds using an organic solvent such as hexane or methylene chloride or may be extracted by supercritical extraction or extraction by compression extraction And is preferably a squeeze extraction. The extraction time and method may be suitably selected by those skilled in the art and may be performed in a single or multiple cycles ranging from about 1 hour to 10 days, but is not limited thereto.

The content of the ginseng seed extract in the composition of the present invention can be appropriately adjusted according to the body weight, age, sex, health condition, diet, etc. of the subject and is 5 to 80% by weight, preferably 10 to 50% But is not limited thereto.

The non-alcoholic fatty liver according to the present invention is caused by excessive fat accumulation in hepatocytes due to liver fat metabolism disorder, and is caused by high fat diet, obesity, diabetes, hyperlipemia, drug and the like.

The hyperlipemia according to the present invention refers to a state in which many lipid ingredients are present in the blood and accumulate in the blood vessel walls to cause inflammation, resulting in cardiovascular diseases and the like.

For the prevention and treatment of gastric non-alcoholic fatty liver and / or hyperlipidemia, the composition of the present invention preferably administers 100 mg to 500 mg per kg body weight per day based on the weight of the ginseng seed extract, It is preferable to administer them two or three times.

The pharmaceutical composition of the present invention can be administered in various formulations, oral and parenteral, at the time of actual clinical administration. In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants which are usually used.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations can be prepared by incorporating into the pharmaceutical composition of the present invention at least one or more excipients such as starch, calcium carbonate, sucrose, lactose And gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. have.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like may be used as a base for suppositories. The pharmaceutical composition of the present invention can be administered by parenteral administration by subcutaneous injection, intravenous injection, or intramuscular injection.

The present invention provides a health functional food for prevention and improvement of a non-alcoholic fatty liver including a ginseng seed extract.

The present invention provides a health functional food for prevention and improvement of hyperlipidemia comprising ginseng seed extract.

The health functional food according to the present invention has a remarkable effect on prevention and improvement of non-alcoholic fatty liver and / or hyperlipemia through the action effects such as inhibition of fat accumulation in liver and improvement of blood lipid concentration.

 "Health functional food" refers to foods manufactured and processed using raw materials or ingredients having useful functions in accordance with the Health Functional Food Act, and "functional" refers to the structure and function of the human body It is meant to be ingested for the purpose of obtaining a beneficial effect for health use such as controlling nutrients or physiological action.

The health functional food composition of the present invention may contain conventional food additives, and the suitability of the term "food additives" for the purpose of the present invention is not limited by the general provisions of the Food Additives Ordinance approved by the Food and Drug Administration, It shall be judged according to standards and standards for items.

Examples of the substances described in the above-mentioned "Food Additive Code" include natural compounds such as ketones, chemical compounds such as glycine, potassium citrate, nicotinic acid and cinnamic acid, persimmon extracts, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent and the like.

The health functional food of the present invention can be variously used for foods and beverages for non-alcoholic fatty liver and / or hyperlipidemia and can be used for various foods, beverages, gums, tea, vitamin complex, health functional auxiliary food, And may be in the form of powders, granules, tablets, capsules or beverages. May be in any food form other than those described above.

The health functional food of the present invention may contain minerals containing compounds such as vitamin B, C, E, beta carotene, Ca, Mg and Zn, phospholipids such as lecithin or components such as maltol, oligosaccharide and amino acid as auxiliary components in addition to ginseng seed extract In particular, when two or three components such as vitamin C, E, beta-carotene and maltol are mixed and used, the bioactive effect can be reinforced, which is preferable.

In addition to the above components, in order to further improve the taste, it is possible to use natural additives such as natural fragrance such as plum, lemon flavor, pineapple flavor or herb flavor, natural fruit juice, florophylline, Fructose, honey, sugar alcohol, sugar, citric acid, and sodium citrate may be added.

When the health functional food of the present invention is in the form of a drink, various flavoring agents, natural carbohydrates, and the like may be added as additional components such as ordinary beverages. Natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

In addition, the health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and rings for the purpose of nonalcoholic fatty liver and / or hyperlipidemia.

For example, the health functional food in the form of tablets may be prepared by granulating a mixture of ginseng seed extract, excipient, binder, disintegrant, and other additives in a conventional manner and then compression- Can be directly compression molded. The health functional food of the tablet form may contain a mating agent and the like if necessary, and may be sieved to a suitable skin care agent if necessary.

The hard capsule of the capsule type health functional food can be prepared by filling a normal hard capsule with a mixture of additives such as ginseng seed extract and an excipient, or a granular material thereof or a granulated material thereof. The soft capsule is prepared from ginseng seed extract , And additives such as excipients into a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.

The ring-shaped health functional food can be prepared by molding a mixture of ginseng seed extract, excipient, binder, disintegrant and the like in an appropriate manner. If necessary, it may be mixed with white sugar or other suitable skin care agent, or starch, talc or suitable substance It is possible that the

The granular health functional food may be prepared by granulating a mixture of ginseng seed extract, excipient, binder, disintegrant and the like in an appropriate manner, and may contain a flavoring agent, a mating agent and the like if necessary. In the next granularity test using 12 (1680 ㎛), 14 (1410 ㎛) and 45 (350 ㎛) sieves, the granule - type health functional food passed through all 12 tongues and remained in 14 tongues 5.0% or less and that passing through the 45-well body may be 15.0% or less of the total amount.

The definitions of the above excipients, binders, disintegrants, lubricants, mating agents, flavors, etc. are described in documents known in the art and include the same or similar functions.

The composition according to the present invention has a remarkable effect on the prevention, treatment and improvement of nonalcoholic fatty liver and / or hyperlipemia through the action effects such as inhibition of accumulation of fat in the liver and improvement of blood lipid concentration.

FIG. 1 shows the results of confirming the effect of inhibiting the accumulation of triglycerides by treatment with ginseng seed extract.
FIG. 2 shows the result of checking the weight change according to the treatment of the ginseng seed extract in an animal model of a high fat diet.
FIG. 3 shows the results of confirming the effect of the high-fat diet on the increase of serum LDL, the decrease of LDL / HDL ratio, and the decrease of serum triglyceride according to the treatment of ginseng seed extract in an animal model.
FIG. 4 shows the result of confirming inhibition of fat accumulation in liver tissue by treatment with ginseng seed extract in an animal model of high fat diet.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.

Example 1: Preparation of ginseng seed extract

The ginseng seeds of Panax ginseng were collected from the seeds of 5 year old ginseng cultivated in Chungbuk province of Korea and obtained 7.35 ㎏ of ginseng seeds by peeling 60 ㎏ of ginseng seeds. The obtained ginseng seeds were roasted for 10 minutes And then pressed to obtain 1.65 kg (about 2 L).

<Example 2> Confirmation of inhibition of intracellular triglyceride accumulation by treatment with ginseng seed extract

The HepG2 human hepatoma cell line was purchased from the American Type Culture Collection (ATCC) and used in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 units / ml penicillin / streptomycin It was incubated at% CO ₂ conditions. HepG2 cells were seeded in a 6-well plate at 1 × 10 ⁵ cells / well to produce a fatty liver cell model. After 24 hours of seeding, a mixture of free fatty acid (FFA) mixed with palmitate and oleate in a 1: mM, and cells were cultured in 1% BSA-DMEM to induce fat accumulation.

(GSO) at 25 μg / ml and 50 μg / ml for 2 hours and metformin (Met) at 2 mM for 2 hours in the positive control group. And the changes of fat accumulation were confirmed by measurement of Oil red O and intracellular triglyceride.

For oil Red O staining, stained cells were washed three times with ice-cold phosphate buffered saline (PBS) and fixed with 10% formaldehyde for 1 hour. The cells were stained with Oil Red O solution for 1 hour, washed with distilled water and observed with an optical microscope (Olympus CKX41, Tokyo, Japan). After observation, the cells were dyed with oil red O stained with isoprophyl alcohol, and the absorbance was measured at 540 nm to quantitatively determine intracellular lipid accumulation.

To quantitatively measure intracellular triglyceride, cells were washed twice with ice-cold PBS and lysed with lysis buffer (1x PBS, 2% trione X-100). The cell lysate was centrifuged, and the supernatant was taken. The amount of neutral fat was measured using asan sulfate neutral fat solution, and the calibration was made at the protein concentration.

The experimental results are shown in Fig.

FIG. 1 shows the results of confirming that fat accumulation is inhibited by treatment of ginseng seed oil in human liver cancer cells. FIG. 1 (A) shows the result of inducing fat accumulation with free fatty acid after treatment with ginseng seed oil in HepG2 cells and staining with Oil Red O solution. FIG. 1 (B) shows the result of dyed Oil Red O solution dyed with 100% isopropanol The results are shown in Fig. As can be seen from FIGS. 1A and 1B, it was confirmed that fat accumulation was reduced in a concentration-dependent manner upon treatment with ginseng seed oil extract.

The results of measurement of the content of intracellular triglyceride are shown in Fig. As shown in Fig. 1C, the decrease in the triglyceride level was confirmed by the concentration of the ginseng seed oil extract in a concentration-dependent manner.

From the above results, it was confirmed that ginseng seed oil has an effect of inhibiting fatty accumulation by fatty acid.

Example 3: Weight loss reduction of ginseng seed extract treatment in an animal model of a high fat diet system

Five - week - old C57BL / 6J mice were fed high fat diet to induce fatty liver and evaluated the efficacy of ginseng seed oil extracts in animal models. Experimental animals were kept in plastic mouse cages and maintained in a laboratory animal room at 23 ± 2 ° C, 50 ± 10% relative humidity and light / dark cycle (12/12 hr), and water and feed were freely taken The experiment was carried out after adaptation to the environment for one week before starting. Experimental groups were divided into three groups: Group (RD) and High Fat Diet (HFD) high fat diet, orally administered with 500 mg / kg / day of ginseng seed oil (HFD + GSO500) The number of animals was 8. Dietary intake and weight change were measured every week for 12 weeks from the start of the experiment to the end of the experiment.

The results are shown in Fig.

FIG. 2 (A) is a graph showing changes in body weight over 12 weeks after administration of the high fat diet and the ginseng seed oil, and FIG. 2 (B) shows the result of ascertaining the increased body weight. When the total weight gain during the experimental period was calculated, the weight gain was reduced by 15.3% in the high-fat diet group treated with 500 mg / kg / day of the ginseng seed oil extract compared with the control group.

From the above results, it was confirmed that the extract of ginseng seed oil inhibited the body weight gain by the high fat diet.

Example 4 Improvement of Blood Lipid Index by Treatment of Ginseng Seed Extract in Animal Model of Highland Method

The change of blood lipid level was confirmed using the animal model of the high fat diet of Example 3 above. At the end of the experiment, blood lipids were collected for 12 h before sacrifice for analysis of serum lipid profiles, and serum was separated by centrifugation and used for analysis. Serum total cholesterol, low density lipoprotein (LDL) and triglyceride were measured using a measurement kit (Stanbio Laboratody, Boerne, TX) and an automatic analyzer (SMARTLAB, Mannheim, Germany).

The results are shown in Fig.

FIG. 3 shows the results of confirming the effect of the ginseng seed oil on the lipid profile of the blood by the high fat diet method. It was confirmed that the blood concentration of the low density lipoprotein cholesterol (A in FIG. 3) and the triglyceride (C in FIG. 3) increased in the ginseng seed oil treatment group due to the high fat diet administration. It was confirmed that the ratio of low density lipoprotein to high density lipoprotein cholesterol was lowered in the group treated with the ginseng seed oil (FIG. 3B).

From the above results, it was confirmed that ginseng seed oil has the effect of improving the hyperlipidemia and nonalcoholic fatty liver caused by high fat diet.

Example 5 Improvement of Blood Lipid Index by Treatment of Ginseng Seed Extract in Animal Model of Highland Method

Histopathological changes of the liver were confirmed using the animal model of the high fat diet method of Example 3 above.

To confirm the morphology of the liver tissue, hepatocytes were sacrificed at 10% neutral buffered formalin, dehydrated and embedded, paraffin blocks were prepared, and 5 .mu.m thick coronal sections were stained with hematoxylin and eosin (H & E) Morphological observation was made with an optical microscope.

The results are shown in Fig.

Fig. 4 shows the results of histological examination of the effects of ginseng seed oil on lipid accumulation in the liver by high fat diet. Morphological observation of lipid accumulation in liver tissues by H & E staining revealed that there were markedly more lipid droplets in the control group than in the control group, which was significantly reduced in the ginseng seed oil treated group. From the above results, it was confirmed that the ginseng seed oil inhibits lipid accumulation in the liver due to the high fat diet.

&Lt; Formulation Example 1 > Preparation of tablets

The ginseng seed extract of Example 1 ... 200 mg

Lactose .......................................... 100㎎

Starch .......................................... 100㎎

Magnesium stearate ............................ Amount

The tablets are prepared by combining the above components and tableting according to a conventional method for producing tablets.

&Lt; Formulation Example 2 > Preparation of capsules

The ginseng seed extract of Example 1 ... 200 mg

Lactose ........................................... 50mg

Starch ........................................... 50mg

Talc ............................................ 2mg

Magnesium stearate ............................ Amount

The above components are combined and filled into gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

&Lt; Formulation Example 3 > Preparation of solution

Ginseng seed extract of Example 1 1000 mg

Sugar .......................................... 20g

Isomeric sugar ...................................... 20g

Lemon flavor ........................................

Purified water was added to make a total volume of 1000 ml. The above components are compounded according to a conventional method for producing a liquid agent, and then filled in a brown bottle and sterilized to prepare a liquid agent.

Although the composition ratio is a composite composition of the preferred embodiment as a relatively suitable ingredient for the beverage, the blending ratio may be arbitrarily varied depending on the regional and national preferences such as the demand level, the demanding country, and the intended use.

Formulation Example 4 Preparation of Health Functional Foods

Ginseng seed extract of Example 1 1000 mg

Vitamin complexes ......................................

Vitamin A Acetate .............................. 70 ㎍

Vitamin E ......................................... 1.0 mg

Vitamin B1 ........................................ 0.13 mg

Vitamin B2 ........................................ 0.15 mg

Vitamin B6 .......................................... 0.5 mg

Vitamin B12 ........................................ 0.2 ㎍

Vitamin C ........................................... 10 mg

Biotin ............................................. 10 μg

Nicotinic acid amide ....................................... 1.7 mg

Folic acid ................................................ 50 G

Calcium pantothenate ....................................... 0.5 mg

Mineral Complex ..........................................

Ferrous sulfate .......................................... 1.75 mg

Zinc oxide ........................................... 0.82 mg

Magnesium carbonate ....................................... 25.3 mg

Potassium Phosphate ......................................... 15 mg

Secondary calcium phosphate ...................................... 55 mg

Potassium citrate ........................................... 90 mg

Calcium carbonate ............................................ 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamins and mineral complexes is a composite composition which is comparatively suitable for a health functional food as a preferred embodiment, the compounding ratio thereof may be arbitrarily modified, and the above components may be compounded And then used in the manufacture of a health functional food composition (for example, a nutritious candy, etc.) by a conventional method.

&Lt; Formulation Example 5 > Preparation of health functional beverage

Ginseng seed extract of Example 1 ... 1000 mg

Citric acid ........................................ 1000 mg

Oligosaccharides ....................................... 100 g

Plum concentrate ....................................... 2 g

Taurine ........................................... 1 g

Purified water was added to the whole ... 900 ml

The above components were combined according to a conventional health functional beverage manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring. The resulting solution was filtered and sterilized in a sterilized 2 L container, And is used in the production of the health functional beverage composition of the present invention.

Although the composition ratio is a composite composition of the preferred embodiment as a relatively suitable ingredient for the beverage, the blending ratio may be arbitrarily varied depending on the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (6)

A pharmaceutical composition for prevention and treatment of nonalcoholic fatty liver including ginseng seed extract. [Claim 2] The pharmaceutical composition according to claim 1, wherein the ginseng seed extract is ginseng seed oil. [Claim 3] The pharmaceutical composition according to claim 2, wherein the ginseng seed oil is ginseng seed oil extracted by a compression extraction method. A health functional food for prevention and improvement of nonalcoholic fatty liver including ginseng seed extract. [Claim 5] The health food according to claim 4, wherein the ginseng seed extract is a ginseng seed oil. [Claim 6] The health food according to claim 5, wherein the ginseng seed oil is a ginseng seed oil extracted by a compression extraction method.

Images